SOLID SCIENCE - NEAR TERM GROWTH OPPORTUNITY
Gene therapy is one of the hottest growth areas in biotech with more than $9 Billion invested in a2018, up 64% from 2017 2017.
Cellastra is targeting dermal scarring, a market expected to double to35 B USD by 2025.
CELLEXA Gene Therapy applied in the wound area switches on the pproduction of natural anti-scarring peptides already found to be safe and effective in clinical studies to date.
Rather than trying to apply topical treatment for weeks or months , one treatment with CELLEXA turns on the cell factory in teach xell of he targeted wound area to produce anti-scarring peptides for many months
See Investor Contacts: